Supplemental Figure S2 from Enhancing Standard of Care Chemotherapy Efficacy Using DNA-Dependent Protein Kinase (DNA-PK) Inhibition in Preclinical Models of Ewing Sarcoma | Synapse
August 1, 2024Open Access
Supplemental Figure S2 from Enhancing Standard of Care Chemotherapy Efficacy Using DNA-Dependent Protein Kinase (DNA-PK) Inhibition in Preclinical Models of Ewing Sarcoma
Key Points
Key points are not available for this paper at this time.
Abstract
Assessment of cell confluency confirms DNA-PK inhibition selectively synergizes with etoposide